AKBAAkebia Therapeutics, Inc.同业对比
Akebia Therapeutics, Inc. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AKBA本股 | $242M#8 | — | 9.7x#11 | 1.0x#3 | 47.5%#4 | 92.4%#3 | 9.9%#3 | -21.2%#6 | — | — | -68.8%#14 | — |
| TRDA | $267M#1 | — | 1.1x#3 | 10.5x#7 | -87.9%#11 | -319.0%#16 | -621.1%#8 | -61.6%#8 | — | — | 34.6%#7 | — |
| BCYC | — | — | — | — | 105.8%#3 | -29.5%#12 | -340.4%#7 | -42.9%#7 | -794.1%#2 | — | — | — |
| LYEL | $260M#2 | — | 1.1x#2 | 7229.0x#11 | -41.0%#9 | 20.0%#6 | -748344.4%#12 | -117.4%#11 | — | — | — | — |
| CAMP | $259M#3 | — | — | 73.9x#9 | 436.5%#2 | -55.2%#13 | -1502.4%#9 | — | — | — | 58.8%#5 | — |
| GLSI | $258M#4 | — | 82.9x#12 | — | — | -11.2%#9 | — | -621.1%#13 | — | — | 55.7%#6 | — |
| MGNX | $258M#5 | — | 6.0x#9 | 1.7x#4 | -0.3%#7 | -11.4%#10 | -48.7%#5 | -0.2%#4 | — | — | 162.7%#1 | — |
| FHTX | $248M#6 | — | — | 8.0x#6 | 36.8%#5 | 14.2%#8 | -279.5%#6 | — | — | — | -14.2%#10 | — |
| RNAC | $242M#7 | — | — | 606.2x#10 | -99.0%#12 | -68.3%#15 | -35851.3%#11 | — | — | — | -12.7%#9 | — |
| ALXO | $241M#9 | — | 1.8x#8 | — | — | 24.6%#5 | — | -74.7%#9 | -84.4%#1 | — | 64.6%#4 | — |
| WHWK | $232M#10 | — | 1.3x#4 | 32.5x#8 | -72.5%#10 | 67.7%#4 | -1601.1%#10 | -11.3%#5 | — | — | 107.9%#3 | — |
| NATR | $232M#11 | 13.2x#1 | 1.7x#7 | 0.5x#1 | 5.7%#6 | 153.7%#1 | 5.2%#4 | 14.3%#2 | — | 9#1 | -19.9%#11 | — |
| ZNTL | $225M#12 | — | 1.6x#6 | — | -100.0%#13 | 17.4%#7 | — | -95.4%#10 | — | — | 120.8%#2 | — |
| SIGA | $220M#13 | — | 1.3x#5 | 2.3x#5 | -31.8%#8 | -60.7%#14 | 25.1%#2 | 14.1%#3 | — | — | -57.8%#13 | 19.6%#1 |
| KROS | $219M#14 | — | 0.8x#1 | 0.9x#2 | 6775.0%#1 | 146.4%#2 | 27.7%#1 | 33.2%#1 | — | — | -29.1%#12 | — |
| ELDN | $214M#15 | — | 6.5x#10 | — | — | -26.1%#11 | — | -138.2%#12 | — | — | 8.4%#8 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议